Latest Cancer: Bladder news
Adjuvant Pembrolizumab Improves Survival in Muscle-Invasive Urothelial Cancer
posted September 20th
by modernClinician Editorial Team
by modernClinician Editorial Team
Socioeconomic Disparities Impact Immunotherapy Use in Urologic Cancers
posted September 6th
by modernClinician Editorial Team
by modernClinician Editorial Team
FDA Approves Anktiva for BCG-Unresponsive, Non-Muscle Invasive Bladder Cancer
posted April 26th
by modernClinician Editorial Team
by modernClinician Editorial Team
Erdafitinib Improves Survival in Metastatic Urothelial Cancer With FGFR Mutation
posted October 23rd
by modernClinician Editorial Team
by modernClinician Editorial Team
Editor's Recommendations
.jpg)
Most Specialty Oral Anticancer Meds for Blood Cancers Are Initially Rejected by Insurers 
Drug Interactions Reducing Contraceptive Effectiveness Common in Epilepsy 
Urine Cell-Free RNA Shows Promise as Biomarker for Bladder Cancer 
1 in 3 With Lupus Take Supplements, Medications With Potential for Interactions Related Articles
ASTRO Issues Guidance for Use of Radiation Therapy in Bladder Cancer 
Enfortumab Vedotin-Pembrolizumab More Effective for MIBC Than Cisplatin-Gemcitabine 
Perioperative Enfortumab Vedotin + Pembrolizumab Tied to Improved Outcomes With Bladder Cancer Monthly Specialist Briefings
Stay Connected
